CClinicalTrials.gg
Status unknownNCT02757118Updated Apr 29, 2016

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery

An interventional study of Intravenous Crystalloid and Intravenous HES in Cardiac Surgery, sponsored by Konkuk University Medical Center. Status unknown. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-29.

Sponsored by Konkuk University Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2016), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).

All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.

According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.

Patient data and statistical analyses:

Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.

All statistical analyses will be performed after the 30th patient's discharge and data acquisition

02

Conditions studied

  • Cardiac Surgery

Keywords

  • Cardiac Surgery, blood viscosity
03

In context

Lead sponsor

Konkuk University Medical Center is the lead sponsor of 93 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients undergoing coiling embolization procedure due to cardiac surgery
  • Patients provided a written informed consent.
  • Patients with preoperative serum hemoglobin concentration >13 g/dL (male) and >12 g/dL (female)
  • Patients with PaO2/FiO2 ratio >150

Exclusion criteria

Exclusion Criteria:

  • Patients with history of anemia, dyspnea, active infection.
  • Patients with endocrine disease
  • Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing cardiac surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Intravenous Crystalloid

    crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

    Drug: Intravenous Crystalloid

  • Active comparator
    Intravenous HES

    HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

    Drug: Intravenous HES

Interventions

  • DrugIntravenous Crystalloid

    crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

  • DrugIntravenous HES

    HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

06

What researchers measure

Primary outcomes

  1. whole blood viscosity

    Time frame: with 1 hour after the completion of procedure

Secondary outcomes

  1. PaO2/FiO2 ratio

    PaO2/FiO2 ratio measured by arterial blood gas analysis

    Time frame: with 1 hour after the completion of procedure

  2. hematocrit

    serum hematocrit, %

    Time frame: with 1 hour after the completion of procedure

  3. glucose

    serum glucose level, g/dl

    Time frame: with 1 hour after the completion of procedure

  4. osmolarity

    serum osmolarity, mOsm

    Time frame: with 1 hour after the completion of procedure

  5. urine output

    hourly urine output, ml/hr

    Time frame: with 1 hour after the completion of procedure

  6. Maximum clot formation

    Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm

    Time frame: with 1 hour after the completion of procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02757118
Lead sponsor
Konkuk University Medical Center
Responsible party
Tae-Yop Kim, MD PhD (Professor, Konkuk University Medical Center) — Principal investigator
First posted
Apr 29, 2016
Start date
May 2016
Primary completion
Oct 2016 (estimated)
Completion
Jan 2017 (estimated)
Last update
Apr 29, 2016

Study contacts

Tae-Yop Kim, MD, PhD
Contact
taeyop@gmail.com
82-2-2030-5448

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion